Oncohist: hope for patients with myeloid leukemia
The Human Stem Cell Institute invests in the development of a drug for the treatment of blood cancerIn 2008, the Human Stem Cell Institute signed an agreement to purchase a blocking stake in the German biotech company Symbiotec, which holds international patents related to histone H1 and the treatment of blood cancer.
On March 1, 2009, Symbiotec signed a contract with Tytonis, according to which Tytonis will support Symbiotec in the clinical trial of the Oncohist product.
The company Tytonis, founded in 2006 by Dr. H. Luessen, provides advisory services to pharmaceutical companies in their commercial development, in the development and licensing of new medicines.
Oncohist has already passed the first stage of clinical trials in Europe, which proved its safety, as well as indirectly confirming the effectiveness of this drug in the treatment of acute myeloid leukemia. It is worth noting that Oncohist has the status of an "orphan drug". This status is assigned to medicines intended for the treatment of rare dangerous diseases, and assumes the priority position of the drug during clinical trials in Europe, as well as provides an accelerated procedure for its registration.
Symbiotec President, Professor Michael Zeppezauer says: "Our company is extremely proud that Oncohist has successfully passed the first stage of clinical trials." The President of Symbiotec emphasized that he was very satisfied with the alliance with Tytonis, which creates a strong partnership for the development of Symbiotec's corporate business and the promotion of Oncohist.
Dr. Henrik Luessen, President of Tytonis comments: "Given the results of the first stage of clinical trials of Oncohist, we believe that this product has every right to be brought to the market as soon as possible. Investors participating in Symbiotec are helping us to bring a drug to the medical community as quickly as possible that can positively affect the quality of life of many people with cancer."
Portal "Eternal youth" www.vechnayamolodost.ru according to the materials of the press service of the ISC
22.06.2009